References of "Pack, S"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailLong-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
Sorensen, O. H.; Crawford, G. M.; Mulder, H. et al

in BONE (2003), 32(2), 120-126

Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year ... [more ▼]

Limited placebo-controlled data are available to assess the long-term fracture efficacy of bisphosphonates. In order to determine the effects of 5 years of risedronate treatment, we extended a 3-year, placebo-controlled vertebral fracture study in osteoporotic women for an additional 2 years; women who entered the extension study continued to receive 5 mg risedronate or placebo according to the original randomization, with maintenance of blinding. End points included vertebral and nonvertebral fracture assessments, bone mineral density measurements, and changes in biochemical markers of bone turnover. A total of 265 women (placebo, 130; 5 mg risedronate, 135) entered the study extension and 220 (83%) completed the additional 2 years. Fracture results observed in the study extension were consistent with those observed in the first 3 years. The risk of new vertebral fractures was significantly reduced with risedronate treatment in years 4 and 5 by 59% (95% confidence interval, 19 to 79%, P = 0.01) compared with a 49% reduction in the first 3 years. Rapid and significant decreases in markers of bone turnover observed in the first 3 years were similarly maintained in the next 2 years of treatment. Increases in spine and hip bone mineral density that occurred in the risedronate group during the first 3 years were maintained or increased with a further 2 years of treatment. The mean increase from baseline in lumbar spine BMD over 5 years was 9.3% (P < 0.001). This study demonstrates that the effects of risedronate over 3 years on vertebral fracture and BMD are maintained with a further 2 years of treatment. (C) 2003 Elsevier Science (USA). All rights reserved. [less ▲]

Detailed reference viewed: 34 (4 ULg)
Full Text
Peer Reviewed
See detailSustained fracture benefit with five years of risedronate in postmenopausal women
Hosking, D; Sorensen, OD; Mulder, H et al

in BONE (2001), S28

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailRandomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
REGINSTER, Jean-Yves ULg; Minne, H. W.; Sorensen, O. H. et al

in Osteoporosis International (2000), 11(1), 83-91

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with ... [more ▼]

The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n = 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p = 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p = 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease. [less ▲]

Detailed reference viewed: 18 (13 ULg)
Peer Reviewed
See detailRisedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density
Ribot, C; Smith, R; Fogelman, I et al

in Journal of Bone and Mineral Research (1999), 14(S1), 136

Detailed reference viewed: 6 (1 ULg)
Peer Reviewed
See detailRisedronate significantly reduces vertebral and non-vertebral fractures in osteoporotic women
Roux, C; Keller, M; Eastell, R et al

in Journal of Bone and Mineral Research (1999), 14(S1), 538

Detailed reference viewed: 5 (1 ULg)
Peer Reviewed
See detailRisedronate produces dose-dependent increases in bone mineral density in postmenopausal women with low bone mass
Fogelman, I; Ribot, C; Smith, R et al

in Calcified Tissue International (1999), 64(S1), 69

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailRisedronate reduces fracture risk in women with established postmenopausal osteoporosis
Eastell, R; Minne, H; Sorensen, O et al

in Calcified Tissue International (1999), 64(S1), 43

Detailed reference viewed: 7 (2 ULg)
Full Text
Peer Reviewed
See detailRisedronate reduces hip fractures in patients with low femoral neck bone mineral density
Miller, P; Roux, C; McClung, M et al

in Arthritis and Rheumatism (1999), 42(S1), 287

Detailed reference viewed: 5 (2 ULg)